Tag: CYP2D6

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Expanding brand awareness and access to HaluGen’s Psychedelics Genetic Test Kit Vancouver, British Columbia–(Newsfile Corp. – January 18, 2022) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide…

Continue Reading Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron.

Ondansetron Cytochrome P450 2D6Gene symbol: CYP2D6UniProt: P10635 CYP2D6*1xN, Not Available Effect Directly Studied Patients with this genotype in CYP2D6 are ultrarapid metabolizers with an increased risk of poor therapeutic response and vomiting when treated with ondansteron. Details Ondansetron Cytochrome P450 2D6Gene symbol: CYP2D6UniProt: P10635 CYP2D6*2xN Not Available Effect Directly Studied…

Continue Reading Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron.

Genetic Polymorphisms in Xenobiotic Metabolism as Susceptibility Factors for Parkinson’s Disease | Research Project Database | Grantee Research Project | ORD

Genetic Polymorphisms in Xenobiotic Metabolism as Susceptibility Factors for Parkinson’s Disease EPA Grant Number: R827017 Title: Genetic Polymorphisms in Xenobiotic Metabolism as Susceptibility Factors for Parkinson’s Disease Investigators: Chan, Piu Institution: Parkinson’s Institute EPA Project Officer: Hahn, Intaek Project Period: October 1, 1998 through September 30,…

Continue Reading Genetic Polymorphisms in Xenobiotic Metabolism as Susceptibility Factors for Parkinson’s Disease | Research Project Database | Grantee Research Project | ORD

(PDF) Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara | Yasuhiro Tezuka

(PDF) Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara | Yasuhiro Tezuka – Academia.edu Academia.edu uses cookies to personalize content, tailor ads and improve the user experience. By using our site, you agree to our collection of information through the use of cookies. To learn more,…

Continue Reading (PDF) Mechanism-based CYP2D6 inactivation by acridone alkaloids of Indonesian medicinal plant Lunasia amara | Yasuhiro Tezuka

Baystreet.ca – Entheon Biomedical Corp.

02:32 PM EST – Entheon Biomedical Corp. : Announced that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc., is now available for sale in Canada and the United States. Entheon, a biomedical company focused on the research and development of psychedelic…

Continue Reading Baystreet.ca – Entheon Biomedical Corp.

Very important pharmacogene variants in the Blang population

Introduction The use of drugs should be different among diverse ethnic groups because of differences in ethnicity, age, sex, environmental factors and genetic factors. If these differences are ignored, then drug sensitivity, metabolic rate, and adverse reactions are affected, which influences the curative effect of drugs and aggravates the illness…

Continue Reading Very important pharmacogene variants in the Blang population

Pharmacogenomic Testing Improves Psychiatric Drug Selections for Treatment-Intolerant or Treatment-Resistant Patients

Evidence-Based Pharmacogenomic Testing Drug efficacy test results inform alternative medication selections when first-line treatment is ineffective with no guidelines for drug substitutions SAN FRANCISCO, CALIFORNIA, UNITED STATES, December 12, 2021 /EINPresswire.com/ — U.S. and Hong Kong-based Rainbow Genomics launches the Rainbow Psycho-Pharmacogenomic(TM) Testing Services enabling physicians to improve outcomes of…

Continue Reading Pharmacogenomic Testing Improves Psychiatric Drug Selections for Treatment-Intolerant or Treatment-Resistant Patients